Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$43.53
-0.6%
$46.18
$42.96
$63.33
$88.60B0.3313.55 million shs7.68 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$84.09
-0.7%
$83.67
$73.31
$111.20
$210.19B0.3714.88 million shs6.09 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.35
-0.7%
$24.88
$20.92
$29.82
$138.53B0.5546.85 million shs38.64 million shs
Zoetis Inc. stock logo
ZTS
Zoetis
$142.75
-0.5%
$148.98
$139.34
$196.55
$63.27B0.93.03 million shs1.99 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
+0.62%-1.82%-5.20%-7.09%-16.81%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.95%-3.21%+2.35%+2.88%-22.67%
Pfizer Inc. stock logo
PFE
Pfizer
-0.77%-6.64%+2.57%-0.26%-15.66%
Zoetis Inc. stock logo
ZTS
Zoetis
+0.82%+0.38%-3.29%-5.29%-25.54%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$43.53
-0.6%
$46.18
$42.96
$63.33
$88.60B0.3313.55 million shs7.68 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$84.09
-0.7%
$83.67
$73.31
$111.20
$210.19B0.3714.88 million shs6.09 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.35
-0.7%
$24.88
$20.92
$29.82
$138.53B0.5546.85 million shs38.64 million shs
Zoetis Inc. stock logo
ZTS
Zoetis
$142.75
-0.5%
$148.98
$139.34
$196.55
$63.27B0.93.03 million shs1.99 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
+0.62%-1.82%-5.20%-7.09%-16.81%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.95%-3.21%+2.35%+2.88%-22.67%
Pfizer Inc. stock logo
PFE
Pfizer
-0.77%-6.64%+2.57%-0.26%-15.66%
Zoetis Inc. stock logo
ZTS
Zoetis
+0.82%+0.38%-3.29%-5.29%-25.54%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.33
Hold$57.1431.29% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.29
Hold$105.0024.87% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.37
Hold$28.3516.46% Upside
Zoetis Inc. stock logo
ZTS
Zoetis
2.44
Hold$196.7137.80% Upside

Current Analyst Ratings Breakdown

Latest ZTS, MRK, PFE, and BMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/14/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/13/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
10/13/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$84.00 ➝ $95.00
10/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$33.00 ➝ $32.00
10/8/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/8/2025
Zoetis Inc. stock logo
ZTS
Zoetis
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/3/2025
Pfizer Inc. stock logo
PFE
Pfizer
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$28.00 ➝ $30.00
10/2/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Dbs Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeModerate Buy
10/1/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$28.00
9/27/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$47.70B1.86$5.88 per share7.40$8.08 per share5.39
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$64.17B3.27$9.29 per share9.05$18.33 per share4.59
Pfizer Inc. stock logo
PFE
Pfizer
$63.83B2.17$4.29 per share5.67$15.62 per share1.56
Zoetis Inc. stock logo
ZTS
Zoetis
$9.26B6.83$7.09 per share20.12$10.57 per share13.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-$8.95B$2.4817.557.152.2510.58%80.04%14.69%10/30/2025 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.4912.978.490.9425.79%41.05%16.55%10/30/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.8812.968.030.8216.84%21.42%9.12%11/4/2025 (Estimated)
Zoetis Inc. stock logo
ZTS
Zoetis
$2.49B$5.8124.5721.152.2827.83%56.90%19.54%11/4/2025 (Estimated)

Latest ZTS, MRK, PFE, and BMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2025Q3 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.79N/AN/AN/A$16.94 billionN/A
11/4/2025Q3 2025
Zoetis Inc. stock logo
ZTS
Zoetis
$1.64N/AN/AN/A$2.42 billionN/A
10/30/2025Q3 2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.65N/AN/AN/A$11.75 billionN/A
10/30/2025Q3 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.37N/AN/AN/A$17.00 billionN/A
8/5/2025Q2 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.58$0.78+$0.20$0.51$13.43 billion$14.65 billion
8/5/2025Q2 2025
Zoetis Inc. stock logo
ZTS
Zoetis
$1.62$1.76+$0.14$1.61$2.41 billion$2.46 billion
7/31/2025Q2 2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.07$1.46+$0.39$0.64$11.32 billion$12.27 billion
7/29/2025Q2 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.03$2.13+$0.10$1.76$15.92 billion$15.81 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.485.70%N/A100.00%17 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.243.85%N/A49.92%14 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.07%N/A91.49%16 Years
Zoetis Inc. stock logo
ZTS
Zoetis
$2.001.40%N/A34.42%14 Years

Latest ZTS, MRK, PFE, and BMY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/9/2025
Zoetis Inc. stock logo
ZTS
Zoetis
quarterly$0.501.4%10/31/202510/31/202512/2/2025
10/9/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.82%11/7/202511/7/202512/1/2025
9/17/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.625.46%10/3/202510/3/202511/3/2025
7/22/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.814%9/15/20259/15/202510/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.54
1.21
1.11
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.69
1.42
1.17
Pfizer Inc. stock logo
PFE
Pfizer
0.65
1.16
0.85
Zoetis Inc. stock logo
ZTS
Zoetis
1.05
1.76
1.04

Institutional Ownership

CompanyInstitutional Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Zoetis Inc. stock logo
ZTS
Zoetis
92.80%

Insider Ownership

CompanyInsider Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.07%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.09%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Zoetis Inc. stock logo
ZTS
Zoetis
0.16%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
34,1002.04 billion2.03 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.50 billion2.50 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable
Zoetis Inc. stock logo
ZTS
Zoetis
13,800443.18 million442.47 millionOptionable

Recent News About These Companies

Leerink Partnrs Issues Negative Forecast for Zoetis Earnings
William Blair Has Negative Forecast for Zoetis Q3 Earnings
Boston Trust Walden Corp Grows Stake in Zoetis Inc. $ZTS
MGO One Seven LLC Purchases 2,039 Shares of Zoetis Inc. $ZTS
Leerink Partnrs Issues Negative Estimate for Zoetis Earnings
Equitable Trust Co. Sells 1,975 Shares of Zoetis Inc. $ZTS
Index Fund Advisors Inc. Invests $621,000 in Zoetis Inc. $ZTS

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$43.52 -0.28 (-0.63%)
As of 03:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$84.09 -0.61 (-0.72%)
As of 03:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer stock logo

Pfizer NYSE:PFE

$24.34 -0.18 (-0.71%)
As of 03:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Zoetis stock logo

Zoetis NYSE:ZTS

$142.75 -0.71 (-0.49%)
As of 03:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.